These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21321144)

  • 1. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
    Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
    Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
    Endimiani A; Patel G; Hujer KM; Swaminathan M; Perez F; Rice LB; Jacobs MR; Bonomo RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):526-9. PubMed ID: 19901089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates.
    Papoutsaki V; Galani I; Papadimitriou E; Karantani I; Karaiskos I; Giamarellou H
    J Glob Antimicrob Resist; 2020 Mar; 20():98-104. PubMed ID: 31398495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.
    Zhao M; Bulman ZP; Lenhard JR; Satlin MJ; Kreiswirth BN; Walsh TJ; Marrocco A; Bergen PJ; Nation RL; Li J; Zhang J; Tsuji BT
    J Antimicrob Chemother; 2017 Jul; 72(7):1985-1990. PubMed ID: 28444224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan.
    Tseng SP; Wang SF; Ma L; Wang TY; Yang TY; Siu LK; Chuang YC; Lee PS; Wang JT; Wu TL; Lin JC; Lu PL
    J Microbiol Immunol Infect; 2017 Oct; 50(5):653-661. PubMed ID: 28705769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae.
    Yu W; Shen P; Bao Z; Zhou K; Zheng B; Ji J; Guo L; Huang C; Xiao Y
    Int J Antimicrob Agents; 2017 Aug; 50(2):237-241. PubMed ID: 28648647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
    Clancy CJ; Hao B; Shields RK; Chen L; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3521-5. PubMed ID: 24566172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
    Michail G; Labrou M; Pitiriga V; Manousaka S; Sakellaridis N; Tsakris A; Pournaras S
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6028-33. PubMed ID: 24060874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.
    Lagerbäck P; Khine WW; Giske CG; Tängdén T
    J Antimicrob Chemother; 2016 Aug; 71(8):2321-5. PubMed ID: 27334665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing
    Erturk Sengel B; Altinkanat Gelmez G; Soyletir G; Korten V
    J Chemother; 2020 Sep; 32(5):237-243. PubMed ID: 32228228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.